| |
肺癌 |
|
◎
|
A
Randomized Placebo-Controlled Trial of Erlotinib in Patients
with Advanced Non-Small Cell Lung Cancer (NSCLC) Following
Failure of 1st Line or 2nd Line Chemotherapy. A National
Cancer Institute of Canada Clinical Trials Group (NCIC CTG)
Trial 950519 |
|
◎
|
Mediastinal
Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant
Chemotherapy Is Prognostic of Survival in Patients With
Stage IIIA pN2 Non-Small-Cell Lung Cancer: A Multicenter
Phase II Trial |
|
◎
|
Randomized
phase III study of docetaxel (D) versus vinorelbine (V)
for elderly patients (pts) with advanced non-small cell
lung cancer (NSCLC): Results of a West Japan Thoracic Oncology
Group trial (WJTOG9904) |
|
◎
|
Phase
III Randomized Trial of Docetaxel Plus Cisplatin Versus
Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell
Lung Cancer: The Japanese Taxotere Lung Cancer Study Group |
|
◎
|
A
randomized phase III trial of paclitaxel plus carboplatin
with or without bevacizumab in patients with advanced non-squamous
non-small cell lung cancer950609 |
|
◎
|
Determinants
of Tumor Response and Survival with Erlotinib in Patients
with Non-Small-Cell Lung Cancer950707 |
|
◎
|
Randomized,
Multinational, Phase III Study of Docetaxel Plus Platinum
Combinations Versus Vinorelbine Plus Cisplatin for Advanced
Non-Small-Cell Lung Cancer: The TAX 326 Study Group950728 |
|
| |
乳癌 |
|
◎
|
A
randomized phase III trial of paclitaxel versus paclitaxel
plus bevacizumab as first line therapy for locally recurrent
or metastatic breast cancer950526 |
|
◎
|
Trastuzumab
in adjuvant breast cancer950331 |
|
◎
|
Effective
and safety of Trastuzumab combined with Docetaxel in Patients
with human epidermal growth factor receptor 2- positive
metastatic breast cancer administrated as first line treatment
950324 |
|
◎
|
Herceptin
in adjuvant breast cacner950310 |
|
◎
|
Effective
and safety of Trastuzumab as single agent in first line
treatment of Her2-overexpressing metastatic breast cancer
950303 |
|
◎
|
Multinational
study of efficacy and safety of humanized anti-Her2 monoclonal
antibody in women who have Her2-overexpressing metastatic
breast cancer that has progressed after chemotherapy for
metastatic disease 950224 |
|
◎
|
Use
of chemotherapy plus a monoclonal antibody againt her2 for
metastatic breast cancer that overexpresses her2950210 |
|
◎
|
Significantly
higher pathology complete remission rate after neoadjuvant
therapy with trastuzumab, paclitaxel and epirubicin chemotherapy:
Results a randomized trial in human epidermal growth facter
receptor-2 positive breast cancer950127 |
|
◎
|
Trastuzumab
in adjuvant breast cancer950106 |
|
◎
|
Postoperative
dose-dense sequential chemotherapy with epirubicin, followed
by CMF with or without paclitaxel, in patients with high-risk
operable breast cancer: a randomized phase Ⅲ study conducted
by the Hellenic Copperative Oncology Group950106 |
|
◎
|
Phase
Ⅲ trial of epirubicin plus paclitaxel compared with epirubicin
plus cyclophosphamide as first-line chemotherapy for metastatic
breast cancer |
|
◎
|
Randomized
Phase III Study of Docetaxel Compared With Paclitaxel in
Metastatic Breast Cancer |
|
◎
|
Adjuvant
Docetaxel for Node-Positive Breast Cancer |
|
◎
|
Docetaxel
and Doxorubicin Compared With Doxorubicin and Cyclophosphamide
as First-Line Chemotherapy for Metastatic Breast Cancer:
Results of a Randomized, Multicenter, Phase III Trial |
|
|
大腸直腸癌 |
|
◎
|
Randomized
phase III study of irinotecan and 5-FU/FA with or without
cetuximab in the first-line treatment of patients with metastatic
colorectal cancer (mCRC)970111 |
|
◎
|
Cetuximab
plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the
first-line treatment of metastatic colorectal cancer (mCRC)970111 |
|
◎
|
Impact
on quality of life of adding cetuximab to irinotecan in
patients who have failed prior oxaliplatin-based therapy970111 |
|
◎
|
Infusion-related
reactions (IRR) associated with cetuximab plus irinotecan
treatment in patients with irinotecan-resistant metastatic
colorectal cancer (mCRC)970111 |
|
◎
|
Phase
I/II study of cetuximab dose-escalation in patients with
metastatic colorectal cancer (mCRC) with no or slight skin
reactions on cetuximab standard dose treatment (EVEREST):
Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy
data.970111 |
|
◎
|
Randomized
Phase III trial of cetuximab monotherapy plus best supportive
care (BSC) versus BSC alone in patients with pretreated
metastatic epidermal growth factor receptor (EGFR)-positive
colorectal carcinoma: A trial of the National Cancer Institute
of Canada Clinical Trials Group (NCIC CTG) and the Australasian
Gastro-Intestinal Trials Group (AGITG)970111 |
|
◎
|
Oxaliplatin/5FU/LV
in the adjvvant treatment of stage II and stage III colon
cancer: efficacy results with a median follow-up of 4 years |
|
◎
|
A
phase III trial comparing FULV to FULV + oxaliplatin in
stage II or III carcinoma of the colon: Results of NSABP
Protocol C-07 |
|
◎
|
Leucovorin
and Fluorouracil With or Without Oxaliplatin
as First-Line Treatment in Advanced Colorectal Cancer |
|
◎
|
High-dose
bevacizumab improves survival when combined with FOLFOX4
in previously treated advanced colorectal cancer: Results
from the Eastern Cooperative Oncology Group (ECOG) study
E3200. |
|
◎
|
Cetuximab
monotherapy and cetuximab plus irinotecan in irinotecan-refractory
metastatic colorectal cancer |
|
◎
|
High-dose
Bevacizumab in Combination with FOLFOX4 Improve Survival
in Patients with Previously950602 |
|
◎
|
Bevacizumab
plus Irinotecan, Fluorouracil and Leucovorin for Metastatic
Colorectal Cancer950623 |
|
◎
|
Capecitabine
(Xeloda) vs bolus 5-FU/Leucovorin (LV) as adjuvant therapy
for colon cancer950714 |
|
◎
|
A
Randomized Controlled Trial of Fluorouracil Plus Leucovorin,
Irinotecan, and Oxaliplatin Combinations in Patients With
Previously Untreated Metastatic Colorectal Cancer950721 |
|
|
胃癌 |
|
◎
|
Phase
II study of weekly oxaliplatin and 24-h infusion of high-dose
5-fluorouracil and folinic acid in the treatment of advanced
gastric
cancer |
|
◎
|
Phase
II Study of Oxaliplatin, Fluorouracil, and Folinic Acid
in Locally Advanced or Metastatic Gastric Cancer Patients |
|
| |
前列腺癌 |
|
◎
|
Docetaxel
plus Prednisone or Mitoxantrone plus Prednisone for Advanced
Prostate Cancer |
|
◎
|
Docetaxel
and Estramustine Compared with Mitoxantrone and Prednisone
for Advanced Refractory Prostate Cancer |
|
| |
白血病 |
|
◎
|
Early
results of a chemoimmunotherapy regimen of fludarabine,
cyclophosphamide, and rituximab as initial therapy for Chronic
Lymphocytic Leukemia950407 |
|
◎
|
Chemoimmunotherapy
with fludarabine, cyclophosphamide, and rituximab for relapsed
and refractory Chronic Lymphocytic Leukemia950421 |
|
| |
淋巴瘤 |
|
◎
|
Long-term
results of the R-CHOP study in the treatment of elderly
patients with diffuse large B-cell lymphoma: a study by
the Groupe d'Etude des Lymphomes de l'Adulte950505 |
|
◎
|
CVP
chemotherapy plus rituximab compared with CVP as first-line
treatment for advanced follicular lymphoma950512 |
| |
|
|
| |
胰臟癌 |
|
◎
|
Erlotinib
Improves Survival When Added to Gemcitabine in Patients
with Advanced Pancreatic Cancer. A Phase III Trial of the
National Cancer Institute of Canada Clinical Trials Group
(NCIC CTG) 950630 |
| |
|
|
| |
其他 |
|
◎
|
Anagrelide,
a Therapy for Thrombocythemic States：
Experience in 577 Patient |
| |
|